The Biden administration has announced a pilot program that will allow Medicare to cover GLP-1 drugs, such as Ozempic and Wegovy, for weight loss. The initiative, set to begin in 2026, could expand access to these expensive medications for millions of older Americans struggling with obesity.
Program Details and Eligibility
The pilot program will be limited to Medicare beneficiaries with a body mass index (BMI) of 30 or higher, which qualifies as obese. It will also require participants to have a history of cardiovascular disease, as studies have shown that GLP-1 drugs can reduce heart attack and stroke risk. The program will initially cover about 500,000 enrollees over a five-year period.
Currently, Medicare Part D plans are prohibited by law from covering drugs for weight loss alone. The pilot will test whether covering these drugs reduces overall healthcare costs by preventing obesity-related complications like diabetes, heart disease, and joint problems.
Cost and Budget Impact
GLP-1 drugs cost approximately $1,000 per month without insurance. The Congressional Budget Office estimated that expanding coverage to all Medicare beneficiaries with obesity would cost $35 billion over 10 years. However, the pilot program is designed to gather data on long-term savings from reduced hospitalizations and other medical interventions.
“This is a critical step toward addressing the obesity epidemic among seniors,” said Health and Human Services Secretary Xavier Becerra. “We need to understand how these drugs can improve health outcomes while managing costs.”
Industry and Advocacy Reactions
Pharmaceutical companies, including Novo Nordisk and Eli Lilly, have lobbied for Medicare coverage of their weight loss drugs. Patient advocacy groups also praised the move, noting that obesity affects over 40% of Americans aged 60 and older.
“We are thrilled that Medicare is finally recognizing obesity as a disease that requires treatment,” said Dr. Sarah Johnson, president of the Obesity Medicine Association. “This pilot will provide vital evidence for broader coverage.”
Next Steps and Future Implications
The Centers for Medicare & Medicaid Services (CMS) will finalize the pilot design in the coming months, with enrollment expected to begin in early 2027. If successful, the program could pave the way for permanent coverage of weight loss medications under Medicare, potentially reshaping the landscape of obesity treatment in the United States.
